With IT and pharma still continuing to see interest, the next series too looks promising for them, says Yogesh Radke, head of quantitative research at Edelweiss Securities.
first published: Mar 26, 2015 10:45 am
A collection of the most-viewed Moneycontrol videos.
Nifty Struggles Below 26,100 On Weekly F&O Expiry As Rupee Hits New Low| Closing Bell Live
Will Rupee Slide & Expiry Day Caution Keep Nifty Bulls On The Back Foot? | Opening Bell Live
Sensex, Nifty Retreat After Hitting Fresh Highs As Rupee Drops To Record Low| Closing Bell Live
Will Solid Q2 GDP Set The Ball Rolling For Nifty Bulls To Cross 26,300 Decisively?|Opening Bell Live
